查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1662670

预测和预后测试市场预测至 2030 年：按类型、适应症、技术、样本、最终用户和地区进行的全球分析

Predictive Presymptomatic Testing Market Forecasts to 2030 - Global Analysis By Type (Genetic Testing, Biochemical Testing, Molecular Testing and Other Types), Indication, Technology, Sample, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球预测和预测测试市场预计在 2024 年将达到 56 亿美元，到 2030 年将达到 109 亿美元，预测期内的复合年增长率为 11.6%。预测和预后测试是一种遗传方法，用于在症状出现之前识别有患上某些遗传疾病风险的个体。透过分析 DNA 来检测与特定疾病相关的突变和标记，例如亨廷顿氏舞蹈症、某些癌症、心血管和神经退化性疾病。该测试将评估未来患有该疾病的可能性，以便采取改变生活方式和加强监测系统等预防措施。

根据2021年发表在Frontiers上的一篇论文，日本罕见遗传疾病的发生率不到每2500人中的1人。

提高对遗传疾病的认识与发病率

随着越来越多人意识到自己的遗传倾向，对早期检测以便及时介入的需求也日益增长。癌症、心血管疾病和神经系统疾病等遗传疾病的发生率不断上升，进一步增加了预测检测的需求。旨在提高遗传素养的政府措施和公共卫生宣传活动也促进了市场的成长。此外，预防性医疗保健实践的日益普及也推动了全球范围内预测性测试的采用。

道德和心理问题

许多人担心了解自己的遗传风险会带来潜在的心理负担，这会导致焦虑和压力。道德困境，包括保险公司和雇主可能滥用基因讯息，也对市场成长构成了挑战。此外，对测试结果的准确性以及假阳性和假阴性的影响的担忧也加剧了人们的犹豫。围绕遗传疾病的文化和社会耻辱进一步限制了此类测试的采用并阻碍了市场成长。

基因检测技术的进展

下一代定序 (NGS) 和基于 CRISPR 的技术等创新正在提高基因检测的准确性、速度和可负担性。这些技术使得与遗传疾病相关的遗传变异的分析成为可能，从而实现了个人化的风险评估。人工智慧（AI）和巨量资料分析的整合进一步支持了预测模型并提高了测试的临床效用。此外，直接面向消费者的基因检测套组的开发将扩大基因检测的管道，为市场成长开闢新的途径。

对准确性和可靠性的担忧

由于检测机构的检测方法和标准不同，检测结果也存在差异，削弱消费者信心。假阳性和假阴性可能导致不适当的医疗决策，进一步影响患者的结果。缺乏通用的基因检测法律规范加剧了这些挑战，并造成了不同地区检测品质的差异。此外，解释遗传资料的复杂性需要专业知识，而这并不总是存在的。总的来说，这些因素威胁着市场的成长潜力，并凸显了强而有力的品质保证措施的必要性。

COVID-19 的影响

COVID-19 疫情对预测测试市场产生了重大影响。一方面，卫生系统和诊断服务的中断减慢了检测程序并减少了患者接受常规筛检的机会。另一方面，这场疫情凸显了预防医学的重要性，并激发了人们对透过基因检测早期发现疾病的兴趣。随着世界进入后疫情时代，市场因重新关注预防性医疗措施而有望復苏和成长。

预测期内，基因检测市场规模预计将达到最大

由于对遗传疾病的早期诊断和干预，预计基因检测领域将在预测期内占据最大的市场占有率。技术进步和对遗传风险认识的提高正在促进这些测试的采用。此外，基于唾液的基因测试等非侵入性测试方法的出现，使得预测预后测试变得更容易取得且更经济实惠。

在预计预测期内，次世代定序 (NGS) 领域将以最高的复合年增长率成长。

由于基因组医学的快速发展和遗传疾病发病率的上升，预计次世代定序 (NGS) 领域将在预测期内呈现最高的成长率。这部分包括一系列受益于早期发现和早期疗育的疾病的测试，包括癌症、心血管疾病和神经系统疾病。价格实惠的基因检测选项的不断增加也有望推动该领域的显着增长。

比最大的地区

预计北美将在预测期内占据最大的市场占有率，这得益于其完善的医疗保健基础设施，以及由于越来越多的个人寻求个性化医疗并提高对个性化医疗的认识而对基因检测的高需求。此外，主要研究机构和专门从事基因检测技术的生物技术公司的存在有助于北美市场占有率。政府推动基因素养和个人化医疗的倡议也有望在帮助北美继续引领市场方面发挥关键作用。

复合年增长率最高的地区

在预测期内，由于医疗保健基础设施的进步、可支配收入的增加以及对预防性医疗保健的日益重视，预计亚太地区将呈现最高的复合年增长率。此外，在政府投资和私营部门倡议的推动下，中国和印度等国家的基因研究和检测能力正在显着增长。随着人们对遗传疾病和基因检测意识的提高，该地区对预测检测的需求可能会激增，特别是在拥有最先进医疗服务的都市区。

免费客製化服务

订阅此报告的客户可享有以下免费自订选项之一：

  • 公司简介
    • 对其他市场参与企业（最多 3 家公司）进行全面分析
    • 主要企业的 SWOT 分析（最多 3 家公司）
  • 地理细分
    • 根据客户兴趣对主要国家进行市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争性基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第 2 章 前言

  • 概述
  • 相关利益者
  • 研究范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二手研究资料资讯来源
    • 先决条件

第三章 市场走势分析

  • 介绍
  • 驱动程式
  • 限制因素
  • 机会
  • 威胁
  • 技术分析
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第 4 章 波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

第五章 全球预测与预测测验市场按类型划分

  • 介绍
  • 基因检测
    • 单基因检测
    • 全基因组序列分析
    • 全EXOME定序
  • 生物化学检验
  • 分子检测
  • 其他的

6. 全球预测与预后测试市场（依适应症划分）

  • 介绍
  • 肿瘤学
  • 神经系统疾病
  • 心血管疾病
  • 内分泌失调
  • 遗传性疾病
  • 其他的

7. 全球预测与预测测试市场（按技术划分）

  • 介绍
  • 新一代定序（NGS）
  • 聚合酵素链锁反应（PCR）
  • 微阵列技术
  • 萤光原位杂合反应（FISH）
  • 其他的

第 8 章。

  • 介绍
  • 血
  • 唾液
  • 组织切片检查
  • 其他范例

第九章。

  • 介绍
  • 医院
  • 诊断实验室
  • 研究和学术机构
  • 专科门诊
  • 其他的

第 10 章。

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司概况

  • 23andMe
  • Abbott Laboratories Inc.
  • Quest Diagnostics Inc.
  • Positive Bioscience
  • Color Genomics
  • Gene by Gene
  • Mapmygenome
  • Myriad Genetics
  • BioAxis DNA Research Center Private Limited
  • Direct Laboratory Services LLC
  • Pathway Genomics Corporation
  • Ambry Genetics Corporation
  • Akonni Biosystems
  • Element Biosciences
  • Eurofins Scientific
  • NGeneBio
Product Code: SMRC28531

According to Stratistics MRC, the Global Predictive Presymptomatic Testing Market is accounted for $5.6 billion in 2024 and is expected to reach $10.9 billion by 2030 growing at a CAGR of 11.6% during the forecast period. Predictive presymptomatic testing is a genetic method used to identify individuals at risk of developing a specific hereditary condition before symptoms appear. It analyzes DNA to detect mutations or markers associated with certain diseases, such as Huntington's disease, certain cancers, and cardiovascular or neurodegenerative disorders. This testing estimates the likelihood of developing a condition in the future; enabling proactive measures like lifestyle changes and increased surveillance.

According to the article published by Frontiers in 2021, in Japan, the rare hereditary disease prevalence was equivalent to less than 1 in 2,500 people.

Market Dynamics:

Driver:

Increasing awareness and incidence of hereditary diseases

As more individuals become aware of their genetic predispositions, there is a growing demand for early testing to enable timely interventions. The increasing prevalence of hereditary conditions such as cancer, cardiovascular diseases, and neurological disorders has further amplified the need for predictive testing. Government initiatives and public health campaigns aimed at promoting genetic literacy also contribute to market growth. Additionally, the growing acceptance of preventive healthcare practices is driving the adoption of predictive presymptomatic testing worldwide.

Restraint:

Ethical and psychological concerns

Many individuals fear the potential psychological burden of knowing their genetic risks, which can lead to anxiety and stress. Ethical dilemmas, including the potential misuse of genetic information by insurers or employers, also pose challenges to market growth. Moreover, concerns about the accuracy of test results and the implications of false positives or negatives add to the hesitancy. Cultural and societal stigma around hereditary diseases further restricts the widespread adoption of these tests hampering the growth of the market.

Opportunity:

Advancements in genetic testing technologies

Innovations such as next-generation sequencing (NGS) and CRISPR-based techniques have enhanced the accuracy, speed, and affordability of genetic testing. These technologies enable comprehensive analysis of genetic variants associated with hereditary diseases, allowing for personalized risk assessment. The integration of artificial intelligence (AI) and big data analytics further supports predictive modeling and enhances the clinical utility of testing. The development of direct-to-consumer genetic testing kits also widens access, creating new avenues for market growth.

Threat:

Accuracy and reliability concerns

Variability in test results due to differences in testing methodologies and laboratory standards undermines consumer trust. False positives or negatives can lead to inappropriate medical decisions, further impacting patient outcomes. The lack of universal regulatory frameworks for genetic testing exacerbates these challenges, creating disparities in test quality across regions. Additionally, the complexity of interpreting genetic data requires specialized expertise, which may not always be available. These factors collectively threaten the market's growth potential and underscore the need for robust quality assurance measures.

Covid-19 Impact

The Covid-19 pandemic significantly influenced the predictive presymptomatic testing market. On one hand, disruptions in healthcare systems and diagnostic services delayed testing procedures and reduced patient access to routine screenings. On the other hand, the pandemic underscored the importance of preventive healthcare, spurring interest in genetic testing for early disease detection. As the world transitions to a post-pandemic phase, the market is poised for recovery and growth, driven by renewed focus on preventive health measures.

The genetic testing segment is expected to be the largest during the forecast period

The genetic testing segment is expected to account for the largest market share during the forecast period owing to early diagnosis and intervention for hereditary diseases. Technological advancements and growing awareness about genetic risks have spurred the adoption of these tests. Furthermore, the availability of non-invasive testing methods, like saliva-based genetic testing, has made predictive presymptomatic tests more accessible and affordable.

The next-generation sequencing (NGS) segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the next-generation sequencing (NGS) segment is predicted to witness the highest growth rate due to rapid evolution of genomic medicine and the rise in hereditary disease incidence are factors contributing to this trend. This segment encompasses tests for a variety of conditions, including cancers, cardiovascular diseases, and neurological disorders, all of which benefit from early identification and intervention. The increasing availability of affordable genetic testing options is also expected to drive substantial growth in this segment.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share owing to well-established healthcare infrastructure, and there is a high demand for genetic testing due to increasing awareness and a growing number of individuals seeking personalized healthcare. Furthermore, the presence of leading research institutions and biotech companies specializing in genetic testing technologies contributes to North America's dominant market share. Government policies promoting genetic literacy and personalized healthcare are also expected to play a significant role in North America's continued market leadership.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR driven by advancements in healthcare infrastructure, rising disposable incomes, and an increasing focus on preventive healthcare. Additionally, countries like China and India are experiencing significant growth in genetic research and testing capabilities, driven by both government investments and private sector initiatives. As awareness around hereditary diseases and genetic testing increases, demand for predictive presymptomatic tests is likely to surge in this region, particularly in urban centers with access to cutting-edge healthcare services.

Key players in the market

Some of the key players in Predictive Presymptomatic Testing market include 23andMe, Abbott Laboratories Inc, Quest Diagnostics Inc, Positive Bioscience, Color Genomics, Gene by Gene, Mapmygenome, Myriad Genetics, BioAxis DNA Research Center Private Limited, Direct Laboratory Services LLC, Pathway Genomics Corporation, Ambry Genetics Corporation, Akonni Biosystems, Element Biosciences, Eurofins Scientific and NGeneBio.

Key Developments:

In January 2024, 23andMe Holding Co. announced the launch of Discover23(R), a new research offering enabling authorized collaborators to securely access the power and diversity of the 23andMe research cohort through a Trusted Research Environment (TRE) developed by Lifebit.

In December 2024, Abbott announced it has reached an agreement with DexCom, Inc. to settle all outstanding patent disputes between the companies in cases related to continuous glucose monitoring products.

In December 2024, Quest Diagnostics launched health coaching on questhealth.com to help individuals take control of their health. The holistic programs focus on several key areas, including general health, weight management, chronic kidney disease, type 2 diabetes, or high cholesterol.

Types Covered:

  • Genetic Testing
  • Biochemical Testing
  • Molecular Testing
  • Other Types

Indications Covered:

  • Oncology
  • Neurological Disorders
  • Cardiovascular Disorders
  • Endocrine Disorders
  • Inherited Conditions
  • Other Indications

Technologies Covered:

  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Microarray Technology
  • Fluorescent In Situ Hybridization (FISH)
  • Other Technologies

Samples Covered:

  • Blood
  • Saliva
  • Tissue Biopsy
  • Other Samples

End Users Covered:

  • Hospitals
  • Diagnostic Laboratories
  • Research & Academic Institutions
  • Specialty Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Predictive Presymptomatic Testing Market, By Type

  • 5.1 Introduction
  • 5.2 Genetic Testing
    • 5.2.1 Single-Gene Testing
    • 5.2.2 Whole Genome Sequencing
    • 5.2.3 Whole Exome Sequencing
  • 5.3 Biochemical Testing
  • 5.4 Molecular Testing
  • 5.5 Other Types

6 Global Predictive Presymptomatic Testing Market, By Indication

  • 6.1 Introduction
  • 6.2 Oncology
  • 6.3 Neurological Disorders
  • 6.4 Cardiovascular Disorders
  • 6.5 Endocrine Disorders
  • 6.6 Inherited Conditions
  • 6.7 Other Indications

7 Global Predictive Presymptomatic Testing Market, By Technology

  • 7.1 Introduction
  • 7.2 Next-Generation Sequencing (NGS)
  • 7.3 Polymerase Chain Reaction (PCR)
  • 7.4 Microarray Technology
  • 7.5 Fluorescent In Situ Hybridization (FISH)
  • 7.6 Other Technologies

8 Global Predictive Presymptomatic Testing Market, By Sample

  • 8.1 Introduction
  • 8.2 Blood
  • 8.3 Saliva
  • 8.4 Tissue Biopsy
  • 8.5 Other Samples

9 Global Predictive Presymptomatic Testing Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Diagnostic Laboratories
  • 9.4 Research & Academic Institutions
  • 9.5 Specialty Clinics
  • 9.6 Other End Users

10 Global Predictive Presymptomatic Testing Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 23andMe
  • 12.2 Abbott Laboratories Inc.
  • 12.3 Quest Diagnostics Inc.
  • 12.4 Positive Bioscience
  • 12.5 Color Genomics
  • 12.6 Gene by Gene
  • 12.7 Mapmygenome
  • 12.8 Myriad Genetics
  • 12.9 BioAxis DNA Research Center Private Limited
  • 12.10 Direct Laboratory Services LLC
  • 12.11 Pathway Genomics Corporation
  • 12.12 Ambry Genetics Corporation
  • 12.13 Akonni Biosystems
  • 12.14 Element Biosciences
  • 12.15 Eurofins Scientific
  • 12.16 NGeneBio

List of Tables

  • Table 1 Global Predictive Presymptomatic Testing Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Predictive Presymptomatic Testing Market Outlook, By Type (2022-2030) ($MN)
  • Table 3 Global Predictive Presymptomatic Testing Market Outlook, By Genetic Testing (2022-2030) ($MN)
  • Table 4 Global Predictive Presymptomatic Testing Market Outlook, By Single-Gene Testing (2022-2030) ($MN)
  • Table 5 Global Predictive Presymptomatic Testing Market Outlook, By Whole Genome Sequencing (2022-2030) ($MN)
  • Table 6 Global Predictive Presymptomatic Testing Market Outlook, By Whole Exome Sequencing (2022-2030) ($MN)
  • Table 7 Global Predictive Presymptomatic Testing Market Outlook, By Biochemical Testing (2022-2030) ($MN)
  • Table 8 Global Predictive Presymptomatic Testing Market Outlook, By Molecular Testing (2022-2030) ($MN)
  • Table 9 Global Predictive Presymptomatic Testing Market Outlook, By Other Types (2022-2030) ($MN)
  • Table 10 Global Predictive Presymptomatic Testing Market Outlook, By Indication (2022-2030) ($MN)
  • Table 11 Global Predictive Presymptomatic Testing Market Outlook, By Oncology (2022-2030) ($MN)
  • Table 12 Global Predictive Presymptomatic Testing Market Outlook, By Neurological Disorders (2022-2030) ($MN)
  • Table 13 Global Predictive Presymptomatic Testing Market Outlook, By Cardiovascular Disorders (2022-2030) ($MN)
  • Table 14 Global Predictive Presymptomatic Testing Market Outlook, By Endocrine Disorders (2022-2030) ($MN)
  • Table 15 Global Predictive Presymptomatic Testing Market Outlook, By Inherited Conditions (2022-2030) ($MN)
  • Table 16 Global Predictive Presymptomatic Testing Market Outlook, By Other Indications (2022-2030) ($MN)
  • Table 17 Global Predictive Presymptomatic Testing Market Outlook, By Technology (2022-2030) ($MN)
  • Table 18 Global Predictive Presymptomatic Testing Market Outlook, By Next-Generation Sequencing (NGS) (2022-2030) ($MN)
  • Table 19 Global Predictive Presymptomatic Testing Market Outlook, By Polymerase Chain Reaction (PCR) (2022-2030) ($MN)
  • Table 20 Global Predictive Presymptomatic Testing Market Outlook, By Microarray Technology (2022-2030) ($MN)
  • Table 21 Global Predictive Presymptomatic Testing Market Outlook, By Fluorescent In Situ Hybridization (FISH) (2022-2030) ($MN)
  • Table 22 Global Predictive Presymptomatic Testing Market Outlook, By Other Technologies (2022-2030) ($MN)
  • Table 23 Global Predictive Presymptomatic Testing Market Outlook, By Sample (2022-2030) ($MN)
  • Table 24 Global Predictive Presymptomatic Testing Market Outlook, By Blood (2022-2030) ($MN)
  • Table 25 Global Predictive Presymptomatic Testing Market Outlook, By Saliva (2022-2030) ($MN)
  • Table 26 Global Predictive Presymptomatic Testing Market Outlook, By Tissue Biopsy (2022-2030) ($MN)
  • Table 27 Global Predictive Presymptomatic Testing Market Outlook, By Other Samples (2022-2030) ($MN)
  • Table 28 Global Predictive Presymptomatic Testing Market Outlook, By End User (2022-2030) ($MN)
  • Table 29 Global Predictive Presymptomatic Testing Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 30 Global Predictive Presymptomatic Testing Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
  • Table 31 Global Predictive Presymptomatic Testing Market Outlook, By Research & Academic Institutions (2022-2030) ($MN)
  • Table 32 Global Predictive Presymptomatic Testing Market Outlook, By Specialty Clinics (2022-2030) ($MN)
  • Table 33 Global Predictive Presymptomatic Testing Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.